

DAFTAR PUSTAKA

1. Adam J. Singer MD, Richard A.F. Clark, M.D. Cutaneous Wound Healing. The New England Journal of Medicine. 1999:738 - 46.
2. Mahsa Tarameshloo MN, Saeed Zarein-Dolab, Masoomeh Dadpay, Roohollah Gazor. A comparative study of the effects of topical application of Aloe vera, thyroid hormone and silver sulfadiazine on skin wounds in Wistar rats. Laboratory Animal Research. 2012;28(1):17 - 21.
3. RISKESDAS. (2013)Riset Kesehatan Dasar. Departemen Kesehatan.160
4. JoAn L. Monaco M, MD, W. Thomas Lawrence, MPH, MD, FACS. Acute wound healing An overview. Clinics In Plastic Surgery. 2003;30:1 - 12.
5. Litwiniuk M, Krejner A, Grzela T. Hyaluronic Acid in Inflammation and Tissue Regeneration. Wounds 2016;28(3):78-88
6. Chithra,G.B.Sajithal and G. Chandrakasan. (1998). "Influence of Aloe veraon Glycosaminoglycans in the Matrix of Healing Dermal Wounds in Rats," Journal of Ethanopharmacology, Vol. 59, No. 3, pp. 179-186. [http://dx.doi.org/10.1016/S0378-8741\(97\)00112-8](http://dx.doi.org/10.1016/S0378-8741(97)00112-8).

7. Paraskevas P, Kontoes 1, C. P. (2010). Wound healing after laser skin resurfacing: The effect of a silver sulfadiazine–hyaluronic acid-containing cream under an occlusive dressing. *Journal of Cosmetic and Laser Therapy*, 12:10-13
8. Dat AD, Poon F, Pham KBT, Doust J. (2011). Aloe vera for treating acute and chronic wounds. *Cochrane Database of Systematic Reviews* 2012, Issue 2. Art. No.: CD008762. DOI: 10.1002/14651858.CD008762. pub2
9. Surjushe, A., Vasani, R., & Saple, D. G. (2008). *Aloe vera*: A Short Review. *Indian Journal of Dermatology*, 53(4), 163–166. doi:10.4103/0019-5154.44785.
10. Pankaj, Sahu, et al. (2013). Therapeutic And Medicinal Uses Of Aloe Vera: A Review. *Pharmacology & Pharmacy*, 2013, 4, 599-610.
11. Marshall JM. Aloe vera gel: What is the evidence? *Pharma Jr.* (1990);24:360–2. Nurdiana, Hariyanto, Musrifah. (2008). Perbedaan kecepatan penyembuhan ;luka bakar derajat II antara perawatan luka menggunakan virgin coconut oil (cocos nucifera) dan normal salin pada tikus putih (rattus novergicus) strain wistar. Skripsi. Malang: FK UB. Hlm 3.

11. Yeh, Eisenberg, T. Kaptchuk and R. S. Phillips. (2003). "Systematic Review of Herbs and Dietary Supplements for Glycemic Control in Diabetes," *Diabetes Care*, Vol. 26, No. 4, 2003, pp. 1277-1294.
<http://dx.doi.org/10.2337/diacare.26.4.1277>
12. Brown. (1980). "A Review of the Genetic Effects of Naturally Occurring Flavonoids, Anthraquinones and Related Compounds," *Mutation Research*, Vol. 75, No. 3, , pp. 243-277.
[http://dx.doi.org/10.1016/0165-1110\(80\)90029-9](http://dx.doi.org/10.1016/0165-1110(80)90029-9)
13. Hayes. (1999). "Lichen Planus: Report of Successful Treatment with Aloe vera," *General Dentistry*, Vol. 47, No. 3, 1999, pp. 268-272.
14. Tyler V. (1993). *The honest herbal: A sensible guide to the use of herbs and related remedies*. 3rd ed. Binghamton, New York: Pharmaceutical Products Press.
15. Saccu, P. (2001). Bogoni and G. Procida, "Aloe Exudate: Characterization by Reversed Phase HPLC and Headspace GC-MS," *Journal of Agricultural and Food Chemistry*, Vol. 49, No. 10, pp. 4526-4530. <http://dx.doi.org/10.1021/jf010179c>
16. Bruneton. (1995). "Pharmacognosy, Phytochemistry, Medicinal Plants," England, Intercept, Hampshire, pp. 434- 436.
17. Rodríguez, D. Hernández-Castillo, R. Rodríguez- García and J. L. Angulo-Sanchez, (2005). "Antifungal Activity in Vitro of Aloe vera Pulp and Liquid Fraction against Plant Pathogenic Fungi," *Industrial Crops*

- and Products, Vol. 21, No. 1, pp. 81-87. <http://dx.doi.org/10.1016/j.indcrop.2004.01.002>.
18. Ito, R. Teradaira, H. Beppu, M. Obata, T. Nagatsu and K. Fujit. (1993). "Properties and Pharmacological Activity of Carboxypeptidase in *Aloe arborescens* Mill. var. *Natalensis* Berger," *Phytotherapy Research*, Vol. 7, No. pp. S26-S29. <http://dx.doi.org/10.1002/ptr.2650070710>
 19. Madan, Sharma, Inamdar, Rao & Singh. (2008). Immunomodulatory Properties of Aloe vera Gel in Mice," *International Journal of Green Pharmacy*, Vol. 2, No. 3, 2008, pp. 152-154.
 20. Ishii, Tanizawa and Y. Takino. 1994. "Studies of Aloe. V. Mechanism of Cathartic Effect. (4)," *Biological & Pharmaceutical Bulletin*, Vol. 17, No. 5, pp. 651-653. <http://dx.doi.org/10.1248/bpb.17.651>
 21. Reynolds and A. C. Dweck. (1999). "Aloe vera Leaf Gel: A Review Update," *Journal of Ethnopharmacology*, Vol. 68, No. 1-3, , pp. 3-37. [http://dx.doi.org/10.1016/S0378-8741\(99\)00085-9](http://dx.doi.org/10.1016/S0378-8741(99)00085-9).
 22. West and Y. F. Zhu. (2003). "Evaluation of Aloe vera Gel Gloves in the Treatment of Dry Skin Associated with Occupational Exposure," Vol. 31, No. 1, *American Journal of Infection Control*, pp. 40-42.
 23. Tanaka, et al. (2006). "Identification of Five Phytosterols from Aloe vera Gel as Antidiabetic Compounds," *Biological and Pharmaceutical Bulletin*, Vol. 29, No. 7, pp. 1418-1422. <http://dx.doi.org/10.1248/bpb.29.1418>

24. Yagi, Y. Sato, Y. Miwa, A. Kabbash, S. Moustafa, K. Shimomura and A. El-Bassuony. (2006). "Ribosomal DNA Sequence Analysis of Different Geographically Distributed Aloe vera Plants: Comparison with Clonally Regenerated Plants," Saudi Pharmaceutical Journal, Vol. 14, No. 3-4, pp. 208-211
25. Sydiskis, D. G. Owen, J. L. Lohr, K. H. Rosler and R. N. Blomster. (1991). "Inactivation of Enveloped Viruses by Anthraquinones Extracted from Plants," Antimicrobial Agents and Chemotherapy, Vol. 35, No. 12, pp. 2463-2466.
[http://dx.doi.org/10.1128/AAC.35.12.2463\[125\]](http://dx.doi.org/10.1128/AAC.35.12.2463[125]) M. Cheesbrough
"Medical Laboratory Manual for Trop
26. Peter. (2002). "Aloe vera Myth or Medicine?" Positive Health Publications,
<http://www.positivehealth.com/permit/Articles/Aloe%20Vera/atherton.htm>
27. Pascal Mallefet ACD. Mechanisms involved in wound healing. The Biomedical Scientist. 2008:609 - 15.
28. Widjajakusumah, Tanzil A., 2014. Guyton and Hall Buku Ajar Fisiologi Kedokteran, edisi 12. Singapore. *Elsevier*
29. Sjamsuhidajat, de Jong., 2016. Buku Ajar Ilmu Bedah, Sistem Organ dan Tindak Bedahnya, edisi 4 vol. 2. Jakarta, Indonesia. *EGC*.

30. McLeod, Mansbridge., 2015. The Innate Immune System in Acute and Chronic Wounds. Durham, North Carolina. *Advances in Wound Care Journal*. <https://www.researchgate.net/publication/276501788>.
31. Thorne, et al., 2007. Grabb and Smith Plastic Surgery, 6th edition. New Yourk, USA. *Lippincot Williams and Wilkins*
32. P. Muangman PA, S. Palapinyo, S. Opananon and A. Chuangsuwanich. Efficacy of the combination of herbal extracts and a silicone derivative in the treatment of hypertrophic scar formation after burn injury. *African Journal of Pharmacy and Pharmacology*. 2011;5(3):442-6. Epub April 7th.

LAMPIRAN

Kruskal-Wallis Test

Ranks			
	Kelompok	N	Mean Rank
PMN_0	AV+SS	3	8.00
	AV	3	5.00
	Kontrol	3	2.00
	Total	9	
PMN_6	AV+SS	3	8.00
	AV	3	4.67
	Kontrol	3	2.33
	Total	9	
PMN_14	AV+SS	3	8.00
	AV	3	4.50
	Kontrol	3	2.50
	Total	9	
Fibrolast_0	AV+SS	3	8.00
	AV	3	4.33
	Kontrol	3	2.67
	Total	9	
Fibrolast_6	AV+SS	3	8.00
	AV	3	4.67
	Kontrol	3	2.33
	Total	9	
Fibrolast_14	AV+SS	3	8.00
	AV	3	5.00
	Kontrol	3	2.00
	Total	9	
Granulasi_6	AV+SS	3	8.00
	AV	3	4.83
	Kontrol	3	2.17
	Total	9	
Granulasi_14	AV+SS	3	8.00
	AV	3	4.50

Kontrol	3	2.50
Total	9	

Test Statistics^{a,b}

	PMN_0	PMN_6	PMN_14	Fibrolast_0	Fibrolast_6	Fibrolast_14	Granulasi_6	Granulasi_14
Chi-Square	7.200	6.489	6.252	6.557	6.489	7.200	6.880	6.252
Df	2	2	2	2	2	2	2	2
Asymp. Sig.	.027	.039	.044	.038	.039	.027	.032	.044

a. Kruskal Wallis Test

b. Grouping Variable: Kelompok

Descriptives

		N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Minimum	Maximum
						Lower Bound	Upper Bound		
PMN_0	AV+SS	3	110.0000	8.00000	4.61880	90.1269	129.8731	102.00	118.00
	AV	3	82.6667	5.03322	2.90593	70.1634	95.1699	78.00	88.00
	Kontrol	3	70.0000	4.00000	2.30940	60.0634	79.9366	66.00	74.00
	Total	9	87.5556	18.43306	6.14435	73.3866	101.7245	66.00	118.00
PMN_6	AV+SS	3	147.3333	19.39931	11.20020	99.1428	195.5239	125.00	160.00
	AV	3	110.0000	10.00000	5.77350	85.1586	134.8414	100.00	120.00
	Kontrol	3	91.6667	12.58306	7.26483	60.4086	122.9247	80.00	105.00
	Total	9	116.3333	27.60888	9.20296	95.1113	137.5554	80.00	160.00
PMN_14	AV+SS	3	121.3333	7.76745	4.48454	102.0379	140.6288	115.00	130.00
	AV	3	93.0000	6.08276	3.51188	77.8896	108.1104	89.00	100.00
	Kontrol	3	85.3333	5.03322	2.90593	72.8301	97.8366	80.00	90.00
	Total	9	99.8889	17.33093	5.77698	86.5672	113.2106	80.00	130.00
Fibrolast_0	AV+SS	3	12.3333	.57735	.33333	10.8991	13.7676	12.00	13.00
	AV	3	9.3333	.57735	.33333	7.8991	10.7676	9.00	10.00
	Kontrol	3	8.6667	.57735	.33333	7.2324	10.1009	8.00	9.00
	Total	9	10.1111	1.76383	.58794	8.7553	11.4669	8.00	13.00
Fibrolast_6	AV+SS	3	30.6667	2.08167	1.20185	25.4955	35.8378	29.00	33.00
	AV	3	23.6667	1.52753	.88192	19.8721	27.4612	22.00	25.00

	Kontrol	3	20.6667	2.08167	1.20185	15.4955	25.8378	19.00	23.00
	Total	9	25.0000	4.74342	1.58114	21.3539	28.6461	19.00	33.00
Fibrolast_14	AV+SS	3	66.0000	5.00000	2.88675	53.5793	78.4207	61.00	71.00
	AV	3	49.6667	3.05505	1.76383	42.0775	57.2558	47.00	53.00
	Kontrol	3	42.0000	2.00000	1.15470	37.0317	46.9683	40.00	44.00
	Total	9	52.5556	11.05793	3.68598	44.0557	61.0554	40.00	71.00
Granulasi_6	AV+SS	3	3.5000	.10000	.05774	3.2516	3.7484	3.40	3.60
	AV	3	1.7333	.25166	.14530	1.1082	2.3585	1.50	2.00
	Kontrol	3	1.2667	.25166	.14530	.6415	1.8918	1.00	1.50
	Total	9	2.1667	1.03682	.34561	1.3697	2.9636	1.00	3.60
Granulasi_14	AV+SS	3	3.6767	.23714	.13691	3.0876	4.2657	3.48	3.94
	AV	3	2.8200	.18248	.10536	2.3667	3.2733	2.70	3.03
	Kontrol	3	2.5867	.15631	.09025	2.1984	2.9750	2.42	2.73
	Total	9	3.0278	.52492	.17497	2.6243	3.4313	2.42	3.94

Post Hoc Tests

Multiple Comparisons

Tukey HSD

Dependent Variable	(I) Kelompok	(J) Kelompok	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
						Lower Bound	Upper Bound
PMN_0	AV+SS	AV	27.33333*	4.83812	.003	12.4887	42.1780
		Kontrol	40.00000*	4.83812	.000	25.1553	54.8447
	AV	AV+SS	-27.33333*	4.83812	.003	-42.1780	-12.4887
		Kontrol	12.66667	4.83812	.088	-2.1780	27.5113
	Kontrol	AV+SS	-40.00000*	4.83812	.000	-54.8447	-25.1553
		AV	-12.66667	4.83812	.088	-27.5113	2.1780
PMN_6	AV+SS	AV	37.33333*	11.87590	.046	.8948	73.7719
		Kontrol	55.66667*	11.87590	.008	19.2281	92.1052
	AV	AV+SS	-37.33333*	11.87590	.046	-73.7719	-.8948
		Kontrol	18.33333	11.87590	.338	-18.1052	54.7719
	Kontrol	AV+SS	-55.66667*	11.87590	.008	-92.1052	-19.2281
		AV	-18.33333	11.87590	.338	-54.7719	18.1052
PMN_14	AV+SS	AV	28.33333*	5.22104	.004	12.3137	44.3529
		Kontrol	36.00000*	5.22104	.001	19.9804	52.0196

	AV	AV+SS	-28.33333*	5.22104	.004	-44.3529	-12.3137
		Kontrol	7.66667	5.22104	.369	-8.3529	23.6863
	Kontrol	AV+SS	-36.00000*	5.22104	.001	-52.0196	-19.9804
		AV	-7.66667	5.22104	.369	-23.6863	8.3529
Fibrolast_0	AV+SS	AV	3.00000*	.47140	.002	1.5536	4.4464
		Kontrol	3.66667*	.47140	.001	2.2203	5.1131
	AV	AV+SS	-3.00000*	.47140	.002	-4.4464	-1.5536
		Kontrol	.66667	.47140	.392	-.7797	2.1131
	Kontrol	AV+SS	-3.66667*	.47140	.001	-5.1131	-2.2203
		AV	-.66667	.47140	.392	-2.1131	.7797
Fibrolast_6	AV+SS	AV	7.00000*	1.56347	.010	2.2028	11.7972
		Kontrol	10.00000*	1.56347	.002	5.2028	14.7972
	AV	AV+SS	-7.00000*	1.56347	.010	-11.7972	-2.2028
		Kontrol	3.00000	1.56347	.214	-1.7972	7.7972
	Kontrol	AV+SS	-10.00000*	1.56347	.002	-14.7972	-5.2028
		AV	-3.00000	1.56347	.214	-7.7972	1.7972
Fibrolast_14	AV+SS	AV	16.33333*	2.91865	.003	7.3781	25.2886
		Kontrol	24.00000*	2.91865	.000	15.0448	32.9552
	AV	AV+SS	-16.33333*	2.91865	.003	-25.2886	-7.3781
		Kontrol	7.66667	2.91865	.087	-1.2886	16.6219
	Kontrol	AV+SS	-24.00000*	2.91865	.000	-32.9552	-15.0448
		AV	-7.66667	2.91865	.087	-16.6219	1.2886
Granulasi_6	AV+SS	AV	1.76667*	.17427	.000	1.2320	2.3014
		Kontrol	2.23333*	.17427	.000	1.6986	2.7680
	AV	AV+SS	-1.76667*	.17427	.000	-2.3014	-1.2320
		Kontrol	.46667	.17427	.081	-.0680	1.0014
	Kontrol	AV+SS	-2.23333*	.17427	.000	-2.7680	-1.6986
		AV	-.46667	.17427	.081	-1.0014	.0680
Granulasi_14	AV+SS	AV	.85667*	.15914	.004	.3684	1.3450
		Kontrol	1.09000*	.15914	.001	.6017	1.5783
	AV	AV+SS	-.85667*	.15914	.004	-1.3450	-.3684
		Kontrol	.23333	.15914	.370	-.2550	.7216
	Kontrol	AV+SS	-1.09000*	.15914	.001	-1.5783	-.6017
		AV	-.23333	.15914	.370	-.7216	.2550

*. The mean difference is significant at the 0.05 level.

Homogeneous Subsets

PMN_0

Tukey HSD^a

Kelompok	N	Subset for alpha = 0.05	
		1	2
Kontrol	3	70.0000	
AV	3	82.6667	
AV+SS	3		110.0000
Sig.		.088	1.000

Means for groups in homogeneous subsets are displayed.

a. Uses Harmonic Mean Sample Size = 3.000.

PMN_6

Tukey HSD^a

Kelompok	N	Subset for alpha = 0.05	
		1	2
Kontrol	3	91.6667	
AV	3	110.0000	
AV+SS	3		147.3333
Sig.		.338	1.000

Means for groups in homogeneous subsets are displayed.

a. Uses Harmonic Mean Sample Size = 3.000.

PMN_14

Tukey HSD^a

Kelompok	N	Subset for alpha = 0.05	
		1	2
Kontrol	3	85.3333	
AV	3	93.0000	
AV+SS	3		121.3333
Sig.		.369	1.000

Means for groups in homogeneous subsets are displayed.

a. Uses Harmonic Mean Sample Size = 3.000.

Fibrolast_0

Tukey HSD^a

Kelompok	N	Subset for alpha = 0.05	
		1	2
Kontrol	3	8.6667	
AV	3	9.3333	
AV+SS	3		12.3333
Sig.		.392	1.000

Means for groups in homogeneous subsets are displayed.

a. Uses Harmonic Mean Sample Size = 3.000.

Fibrolast_6

Tukey HSD^a

Kelompok	N	Subset for alpha = 0.05	
		1	2
Kontrol	3	20.6667	
AV	3	23.6667	
AV+SS	3		30.6667
Sig.		.214	1.000

Means for groups in homogeneous subsets are displayed.

a. Uses Harmonic Mean Sample Size = 3.000.

Fibrolast_14Tukey HSD^a

Kelompok	N	Subset for alpha = 0.05	
		1	2
Kontrol	3	42.0000	
AV	3	49.6667	
AV+SS	3		66.0000
Sig.		.087	1.000

Means for groups in homogeneous subsets are displayed.

a. Uses Harmonic Mean Sample Size = 3.000.

Granulasi_6Tukey HSD^a

Kelompok	N	Subset for alpha = 0.05	
		1	2
Kontrol	3	1.2667	
AV	3	1.7333	
AV+SS	3		3.5000
Sig.		.081	1.000

Means for groups in homogeneous subsets are displayed.

a. Uses Harmonic Mean Sample Size = 3.000.

Granulasi_14Tukey HSD^a

Kelompok	N	Subset for alpha = 0.05	
		1	2
Kontrol	3	2.5867	
AV	3	2.8200	
AV+SS	3		3.6767
Sig.		.370	1.000

Means for groups in homogeneous subsets are displayed.

a. Uses Harmonic Mean Sample Size = 3.000.